Coherent Inc

Name ›

Address/P.O. Box › Postal Code/City › Country ›

Address/P.O. Box › Postal Code/City › Country › Contact Person ›

Telephone › Fax › Email › Website › Number of Employees › Founded (year) › Type of Laboratory ›

Areas of Activity ›

Biological Patents ›

External ›

Collaborations

Request for ›

Further Collaborations CO.DON AG

Warthestr. 21 (Headquarters) 14513 Teltow Germany

Subsidiary: Deutscher Platz 5d 04103 Leipzig Germany Matthias Meißner, M.A. (Director Corporate Communications / IR / PR) +49-341-99190-330 +49-341-99190-309 info@codon.de www.codon.de 150 (2021) 1993 GMP/Integrated Isolator Technology (IIT)

Tissue Engineering

For cell-based human tissue engineering therapeutics

Various ongoing projects with several well-renowned hospitals, universities, and university hospitals in Europe in the field of product distribution, product development, clinical evaluation, and research

CO.DON AG is seeking national and international corporate partners who have substantial resources in the field of tissue engineering and regeneration for distribution and marketing of the company’s products (international) as well as for the development of product lines.

The Company

CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of knee cartilage defects following trauma or degeneration. The medicinal product is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). CO.DON’s method is currently used in over 200 clinics in Germany and more than 17,000 patients have already been treated. In July 2017 CO.DON received EU-wide marketing authorisation for its product, with approval for Switzerland following in March 2019. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: ISIN DE000A3E5C08). Executive Board: Tilmann Bur.

CO.DON AG manufactures cell-based therapies of the highest purity and to the highest quality standards. Its products represent a revolutionary process in the biological regenerative treatment of articular cartilage defects.

The products are 100% autologous and free of additives, setting the stage for the highest level of personalized treatment. Because no exogenous materials are used, the risks of rejection, inflammation, and infection are low. Due to a minimally invasive or arthroscopic application of the product, surgery and rehabilitation time can be reduced.

CO.DON AG is certified in accordance with European Guidelines for Good Manufacturing Practice (EU-GMP) since 1997. In 1997 CO.DON AG was the first biopharmaceutical company in Europe to be granted a permit for the manufacture of autologous chondrocyte transplants under section 13 of the German Drugs Law (AMG).

Innovation in Manufacturing

In January 2020 CO.DON awarded a manufacturing licence for its newly built production plant in Leipzig. This means that the Leipzig site is certified as GMPcompliant at the same time. GMP stands for Good Manufacturing Practice, a binding international standard to ensure the highest safety and quality in pharmaceutical production processes.

The production site is one of the largest and most modern plants for the industrial-scale production of human cells. Routine production started in August 2021 to ensure that our cell therapy products of the highest quality are supplied to our users in Germany and other European countries.

The principle behind the Integrated Isolator Technology originally invented and developed for Teltow has been refined. Its modular construction means the plant is extremely flexible and can be expanded at any time. Currently it consists of 3 isolators and 144 decentralised, mobile incubators, which have a capacity of 4,500 transplants a year. All resource planning and monitoring of the processes required to produce the cell therapy products is computerised.

CO.DON’s technological, production and regulatory expertise makes the company a first mover in the market for biological cartilage regeneration and a provider of highly effective, safe treatment options between pain therapy and endoprothetics with the aim to become market leader in arthrosis prophylaxis. Moreover, the product is currently the only cell-based medicinal product for the regenerative treatment of knee cartilage defects that is authorized EU-wide. With that, CO.DON has the chance to open up a market that is worth millions and to raise its company value. CO.DON founded subsidiaries in Switzerland, the UK and the Netherlands to develop this promising market in line with the company’s strategy Currently, the products are distributed in Germany, the Netherlands, UK, Switzerland, and Austria.